# NCT03829111 (NCT03829111)

> CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03829111
- Phase: PHASE1
- Status: COMPLETED
- Sponsor: City of Hope Medical Center
- Conditions: Advanced Renal Cell Carcinoma; Clear Cell Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8; Unresectable Renal Cell Carcinoma
- Interventions: Clostridium butyricum CBM 588 Probiotic Strain; Ipilimumab; Nivolumab
- Enrollment: 30
- Primary outcome: Change in Bifidobacterium composition of stool

## Commentary we found

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct03829111